Commodore Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001831942

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 33 positions · Total reported value $1.68B · Top-10 concentration 68.2% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 53.7% · 5 new · 9 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +32.0% · vs SPY +17.2% · Prev Value $1.73B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Commodore Capital LP disclosed 33 equity positions with a combined reported value of $1.68B. The filing implies a focused portfolio: its ten largest positions account for 68.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RLAY ($224.52M), ELVN ($166.21M), ALKS ($157.19M). By sector, the heaviest allocations are Health Care 94.7%, Industrials 3.9%. Versus the prior quarter, allocation shifted toward Health Care (+3.3pp), Industrials (+1.8pp) and away from Other (-5.5pp).

Versus the prior quarter, Commodore Capital LP opened 5 new positions, trimmed 9 and fully exited 8, a turnover rate of 53.7% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2026 were TNGX ($70.33M), EDIT ($28.80M), IFRX ($16.35M).

Of the 8 positions fully exited versus the prior quarter, the largest were ERAS ($51.37M), XENE ($47.97M), NRIX ($35.26M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • TNGX TANGO THERAPEUTICS INC · $70.33M
  • EDIT EDITAS MEDICINE INC · $28.80M
  • IFRX INFLARX NV · $16.35M
  • RACC RESEARCH ALLIANCE CORP III · $5.35M
  • VTGN VISTAGEN THERAPEUTICS INC · $630.23K

Fully Exited (vs previous quarter)

  • ERAS ERASCA INC · prev qtr: $51.37M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $47.97M
  • NRIX NURIX THERAPEUTICS INC · prev qtr: $35.26M
  • CRVS CORVUS PHARMACEUTICALS INC · prev qtr: $33.05M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $21.84M
  • OCUL OCULAR THERAPEUTIX INC · prev qtr: $21.81M
  • PALI PALISADE BIO INC · prev qtr: $12.57M
  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $10.86M

Insider Transactions (Form 4)

Latest Commodore Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Commodore Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 33 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-117168 (status: Approved), registered 2019-08-12
  • Regulatory AUM (Form ADV): $2.37B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: commodorecapital.com

Portfolio Structure

  • 33 positions · $1.68B reported value (Q2 2026)
  • Top 10 holdings = 68.2% of reported value
  • Largest position: RLAY (RELAY THERAPEUTICS INC COM) at 13.4%
  • Average position size: $50.88M

Sector Tilt

  • Health Care 94.7%
  • Industrials 3.9%
  • Financials 0.6%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 5 new, 6 added, 9 reduced, 8 exited
  • 13 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Commodore Capital LP appears to be maintaining a cautious approach to their investments, with a focus on health care, particularly biotechnology and pharmaceuticals. The fund's actions suggest a preference for holding onto established positions and selectively increasing exposure to certain companies. 2. Key Moves: - Added: EYPT (EyePoint Inc), a new position in the Industrials sector, which was significantly increased from 2,825,000 to 4,600,000 shares, indicating a substantial bullish outlook on the company. - Reduced: RLAY (Relay Therapeutics Inc) by 5,000,000 shares, reflecting a significant reduction of 29.4% quarter-over-quarter. - Increased: COGT (Cogent Biosciences Inc) by 162,993 shares, showing an increase of 5.6% quarter-over-quarter. - No Change: Positions in ELVN (Enliven Therapeutics Inc), AMLX (Amylyx Pharmaceuticals Inc), DFTX (Definium Therapeutics Inc), ANRO (Alto Neuroscience Inc), and TNGX (Tango Therapeutics Inc) remained unchanged in terms of share count. - Removed: No positions were removed. 3. Portfolio Structure: - Passive/Active: The fund seems to be taking an active approach, with selective additions and reductions in positions. - Sector Bias: The portfolio is heavily biased towards the Health Care sector, particularly in biotechnology and pharmaceuticals. - Risk Appetite: The risk appetite appears moderate, with a preference for established companies and cautious additions or reductions in positions. 4. Per-Holding One-Liner: - RLAY: Relay Therapeutics Inc is a biotechnology company focused on developing novel therapies for cancer and rare diseases. - ELVN: Enliven Therapeutics Inc is a biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. - ALKS: Alkermes PLC is a biopharmaceutical company focused on novel drug delivery systems and novel molecules. - COGT: Cogent Biosciences Inc is a biopharmaceutical company focused on developing treatments for inflammatory diseases. - AMLX: Amylyx Pharmaceuticals Inc is a biotechnology company developing therapies for rare and life-threatening diseases. - DFTX: Definium Therapeutics Inc is a biotechnology company focused on developing therapies for neurological and other diseases. - SYRE: Spire Therapeutics Inc is a biopharmaceutical company focused on developing treatments for rare and orphan diseases. - ANRO: Alto Neuroscience Inc is a biotechnology company focused on developing treatments for neurological diseases. - TNGX: Tango Therapeutics Inc is a biotechnology company focused on developing treatments for rare genetic disorders. - EYPT: EyePoint Inc is an ophthalmic medical device company focused on the development and commercialization of minimally invasive treatments for eye diseases. 5. One-Sentence Style Summary: Commodore Capital LP maintained a cautious approach to its investments in the second quarter of 2026, focusing on selective additions and reductions in its biotechnology and pharmaceutical holdings, with a notable bullish move on EyePoint Inc in the Industrials sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 94.7%
Financials 0.6%
Other 0.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.00M $224.52M 13.37%
13.37%
Reduce
2 3.27M $166.21M 9.90%
9.90%
Hold
3 3.00M $157.19M 9.36%
9.36%
Reduce
4 3.05M $118.03M 7.03%
7.03%
Add
5 5.65M $101.47M 6.04%
6.04%
Hold
6 2.00M $94.08M 5.60%
5.60%
Hold
7 846.79K $75.18M 4.48%
4.48%
Reduce
8 2.72M $71.87M 4.28%
4.28%
Hold
9 2.25M $70.33M 4.19%
4.19%
New
10 4.60M $65.78M 3.92%
3.92%
Add
11 1.88M $59.89M 3.57%
3.57%
Reduce
12 1.94M $50.43M 3.00%
3.00%
Hold
13 1.35M $50.23M 2.99%
2.99%
Reduce
14 1.43M $49.28M 2.94%
2.94%
Reduce
15 1.50M $48.68M 2.90%
2.90%
Hold
16 1.42M $38.88M 2.32%
2.32%
Add
17 8.89M $28.80M 1.72%
1.72%
New
18 250.00K $28.67M 1.71%
1.71%
Reduce
19 6.34M $21.61M 1.29%
1.29%
Hold
20 8.70M $21.30M 1.27%
1.27%
Hold
21 3.25M $19.18M 1.14%
1.14%
Hold
22 1.02M $18.82M 1.12%
1.12%
Add
23 7.30M $16.35M 0.97%
0.97%
New
24 2.93M $14.20M 0.85%
0.85%
Add
25 100.00K $12.35M 0.74%
0.74%
Reduce
26 2.87M $11.19M 0.67%
0.67%
Reduce
27 5.40M $10.96M 0.65%
0.65%
Hold
28 1.43M $9.86M 0.59%
0.59%
Add
29 4.47M $8.05M 0.48%
0.48%
Hold
30 500.00K $5.35M 0.32%
0.32%
New
31 500.00K $5.32M 0.32%
0.32%
Hold
32 464.40K $4.27M 0.25%
0.25%
Hold
33 2.79M $630.23K 0.04%
0.04%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 28% of its Top-10 each quarter and backtests at F1 73% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 73% · recall 73% · F1 73% · avg rank error 2.2 · Top-10 turnover 28%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% MRUS · NUVL · XENE · VERA · PCVX · RYTM · SYRE · IMVT · ARVN · VRDN MRUS · VERA · NUVL · XENE · SYRE · ELVN · PCVX · MNMD · ALPN · ARVN
2024-Q2 70% 70% 70% MRUS · VERA · NUVL · XENE · SYRE · ELVN · PCVX · ARVN · ALPN · MNMD MRUS · NUVL · XENE · PCVX · ELVN · VERA · COGT · SLNO · CLDX · MNMD
2024-Q3 80% 80% 80% MRUS · NUVL · XENE · PCVX · ELVN · COGT · VERA · SLNO · CLDX · ARVN MRUS · VERA · XENE · PCVX · ELVN · NUVL · COGT · ALKS · SLNO · SYRE
2024-Q4 90% 90% 90% MRUS · XENE · PCVX · VERA · ELVN · NUVL · ALKS · COGT · SLNO · VRDN MRUS · PCVX · NUVL · XENE · ELVN · VERA · SLNO · ALKS · NRIX · COGT
2025-Q1 80% 80% 80% MRUS · PCVX · NUVL · XENE · ELVN · VERA · ALKS · SLNO · NRIX · COGT MRUS · NUVL · ELVN · SLNO · XENE · ALKS · AGIO · PCVX · VERA · CLDX
2025-Q2 60% 60% 60% MRUS · NUVL · ELVN · SLNO · XENE · PCVX · CLDX · AGIO · SRRK · VERA MRUS · NUVL · XENE · ELVN · AGIO · CLDX · ALKS · VRDN · PTGX · CDTX
2025-Q3 70% 70% 70% MRUS · NUVL · XENE · ELVN · CLDX · AGIO · VRDN · ALKS · PTGX · CDTX MRUS · NUVL · XENE · COGT · ELVN · AGIO · ALKS · SLNO · RLAY · CLDX
2025-Q4 60% 60% 60% MRUS · COGT · NUVL · XENE · SLNO · ALKS · ELVN · RLAY · AGIO · CLDX RLAY · ALKS · TYRA · XENE · SYRE · COGT · ELVN · CLDX · AMLX · TERN
2026-Q1 80% 80% 80% RLAY · ALKS · TYRA · COGT · SYRE · XENE · AMLX · ELVN · CLDX · SLNO RLAY · ALKS · ELVN · COGT · SYRE · TYRA · CLDX · NUVL · AMLX · KYMR
2026-Q2 ★ 70% 70% 70% RLAY · ALKS · ELVN · COGT · SYRE · TYRA · NUVL · CLDX · AMLX · ANRO RLAY · ELVN · ALKS · COGT · AMLX · DFTX · SYRE · ANRO · TNGX · EYPT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Commodore Capital LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Commodore Capital LP reported 33 equity positions worth $1.68B in aggregate; its largest disclosed positions were RLAY ($224.52M), ELVN ($166.21M), ALKS ($157.19M).

How large is Commodore Capital LP's portfolio?

Commodore Capital LP reported $1.68B of long equity holdings across 33 positions as of 2026-Q2. Top-10 holdings account for 68.2% of reported value.

What is Commodore Capital LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/commodore-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →